Piracetam for Aphasia in Post-stroke Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials

  title={Piracetam for Aphasia in Post-stroke Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials},
  author={Jie Zhang and Ruili Wei and Zhongqin Chen and Ben-yan Luo},
  journal={CNS Drugs},
BackgroundAphasia is a common symptom in post-stroke patients. Piracetam is a commonly used nootropic agent that promises various benefits to brain function, including language improvement.ObjectiveWe performed a systematic review and meta-analysis to assess whether piracetam facilitates the rehabilitation of language performance in post-stroke patients.MethodsRandomized controlled trials (RCTs) of piracetam treatment in post-stroke patients published in any language were included, excluding… 

No evidence of impediment by three common classes of prescription drugs to post-stroke aphasia recovery in a retrospective longitudinal sample

Results offer modest reassurance that these common classes of pharmacotherapy, when given for short periods in this population, do not appear to have marked deleterious effects on post-stroke recovery of language.

Ten key reasons for continuing research on pharmacotherapy for post-stroke aphasia

The extant evidence, though limited, suggests that modulating the activity of neurotransmitter systems with pharmacological interventions is a promising strategy for ameliorating language and communication deficits in PSA.

Effects of Acupuncture-Related Therapies in the Rehabilitation of Patients with Post-Stroke Aphasia—A Network Meta-Analysis of Randomized Controlled Trials

Results of the network meta-analysis and SUCRA ranking showed that tongue acupuncture, body acupuncture + tongueupuncture, and bodyupuncture + scalp acupuncture seem to offer better advantages than other interventions for improving the language function in PSA patients.

Treatment and Prognosis of Aphasia after Stroke

Further research for treatment and prognosis of PSA are indicated with many participants, including varieties of aphasia types, explaining the pathophysiology of these recoveries of the novel approaches and details on the optimal daily dosage, intensity, and duration of these therapies.

The management of subacute and chronic vascular aphasia: an updated review

The existing literature regarding available PSA management options, advances, and drawbacks pertaining to subacute and chronic phases are upgraded, yet the optimal dosage of the emerging high-intensity therapies is controversial.

Post-stroke aphasia management – from classical approaches to modern therapies

A narrative review of widely accepted aphasia classifications and the corresponding management practices, and speech-language therapies are presented, with a focus on the widely preferred patient-centered approach.

Functional recovery differences after stroke rehabilitation in patients with uni- or bilateral hemiparesis

It is demonstrated that differences in functional recovery after stroke rehabilitation may be influenced by the site of hemiparesis after stroke.

A physician survey of poststroke aphasia diagnosis and treatment in China

The knowledge gaps exist among physicians in China regarding the assessment and management of PSA, and the improved awareness of the available guidelines/consensus could improve the performance of the physicians.

Pharmacological Treatment of Post-stroke Cognitive Deficits

The state-of-the-art of pharmacotherapy for PSCD is reviewed together with the theoretical rationale for using drugs in three highly prevalent stroke-related conditions, aphasia, neglect and VCI.



Effect of Low-Frequency rTMS on Aphasia in Stroke Patients: A Meta-Analysis of Randomized Controlled Trials

Low-frequency rTMS with a 90% resting motor threshold that targets the triangular part of the right inferior frontal gyrus (IFG) has a positive effect on language recovery in patients with aphasia following stroke.

Piracetam as an adjuvant to language therapy for aphasia: a randomized double-blind placebo-controlled pilot study.

Effect of Piracetam on Recovery and Rehabilitation After Stroke: A Double‐Blind, Placebo‐Controlled Study

An improvement in aphasia in patients undergoing rehabilitation after a stroke after 12 weeks' treatment with piracetam is shown, but an effect on tests of activities of daily living is unable to be demonstrated and the effect on perceptual deficit is not confirmed.

Piracetam Improves Activated Blood Flow and Facilitates Rehabilitation of Poststroke Aphasic Patients

Piracetam as an adjuvant to speech therapy improves recovery of various language functions, and this effect is accompanied by a significant increase of task-related flow activation in eloquent areas of the left hemisphere.

A Systematic Review and Meta-Analysis of the Efficacy of Piracetam and Piracetam-Like Compounds in Experimental Stroke

The evidence supporting a protective effect of piracetam and its derivatives in animal models of stroke is described, but concerns are raised about the amount of available data, the quality of the studies and publication bias.

Pharmacological treatment for aphasia following stroke.

Drug treatment with piracetam may be effective in the treatment of aphasia after stroke, and researchers should examine the long term effects of this treatment, and whether it is more effective than speech and language therapy.

Poststroke Aphasia

Data from single-case studies, case series and an open-label study suggest that donepezil may have beneficial effects on chronic poststroke aphasia, and preliminary evidence suggests that didpezil is well tolerated and its efficacy is maintained in the long term.

Pharmacotherapy of aphasia.

  • D. Beversdorf
  • Psychology, Medicine
    The Journal of head trauma rehabilitation
  • 2007
Research has focused on stroke due to the focal nature of the lesions and the vascular territories resulting in a more homogeneous patient population for study, so any possible benefits for people with traumatic brain injury must be extrapolated from the studies on subjects with stroke.

Piracetam for acute ischaemic stroke.

Limited data showed no difference between the treatment and control groups for functional outcome, dependency or proportion of patients dead or dependent, and there was some suggestion of an unfavourable effect of piracetam on early death, but this may have been caused by baseline differences in stroke severity.